SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Negrier S,Perol D,Ravaud A, et al. Medroxyprogesterone, inteferon alpha-2a, interleukin-2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Results of a randomized controlled trial. Cancer. 2007; 110: xxxxxx.
  • 2
    Coppin C,Porzsolt F,Awa A,Kumpf J,Coldman A,Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005: CD001425.
  • 3
    Fyfe G,Fisher RI,Rosenberg SA,Sznol M,Parkinson DR,Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688696.
  • 4
    Fisher RI,Rosenberg SA,Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6 suppl 1: S55S57.
  • 5
    Sleijfer DT,Janssen RA,Buter J,de Vries EG,Willemse PH,Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992; 10: 11191123.
  • 6
    Lopez Hanninen E,Kirchner H,Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996; 155: 1925.
  • 7
    Yang JC,Topalian SL,Parkinson D,Schwartzentruber DJ,Weber JS,Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994; 12: 15721576.
  • 8
    Yang JC,Sherry RM,Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 31273132.
  • 9
    McDermott DF,Regan MM,Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133141.
  • 10
    Atzpodien J,Lopez Hanninen E,Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995; 13: 497501.
  • 11
    Rini BI,Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005; 23: 10281043.
  • 12
    Yang JC,Haworth L,Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427434.
  • 13
    Ratain MJ,Eisen T,Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 25052512.
  • 14
    Escudier B,Eisen T,Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125134.
  • 15
    Bukowski RM,Eisen T,Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis [abstract]. J Clin Oncol. 2007; 25: 18S. Abstract 5023.
  • 16
    Motzer RJ,Michaelson MD,Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 1624.
  • 17
    Motzer RJ,Rini BI,Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 25162524.
  • 18
    Motzer RJ,Hutson TE,Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115124.
  • 19
    Hudes G,Carducci M,Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 22712281.
  • 20
    Bui MH,Seligson D,Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9: 802811.
  • 21
    Atkins M,Regan M,McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005; 11: 37143721.